COLL (Collegium Pharmaceutical) Notes Receivable: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COLL Collegium Pharmaceutical Inc COLL
79 GF Score
Price $27.23
GF Value $46.67
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Collegium Pharmaceutical Notes Receivable?

Collegium Pharmaceutical COLL -7.62% 79 Notes Receivable is $0.0 Mil as of Jun. 2026. GuruFocus rates COLL with a GF Score™ of 79/100 and a GF Value™ of $46.67 (Possible Value Trap). The stock has 3 warning signs investors should review.

Collegium Pharmaceutical's Notes Receivable for the quarter that ended in Jun. 2026 was $0.0 Mil.

Collegium Pharmaceutical Notes Receivable Related Terms

Collegium Pharmaceutical Notes Receivable Historical Data

* Premium members only.

The historical data trend for Collegium Pharmaceutical's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Collegium Pharmaceutical Notes Receivable Chart

Collegium Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Collegium Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
COLL
79GF Score
Collegium Pharmaceutical Inc COLL
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Collegium Pharmaceutical Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.0 Mil mean?
Collegium Pharmaceutical (COLL) has a Notes Receivable of $0.0 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Collegium Pharmaceutical and its competitors.
Is Collegium Pharmaceutical's Notes Receivable too high?
Collegium Pharmaceutical's current Notes Receivable is $0.0 Mil. Overall, Collegium Pharmaceutical has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's Notes Receivable compare to ETON and ALVO?
Collegium Pharmaceutical's Notes Receivable of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Collegium Pharmaceutical and its competitors. Collegium Pharmaceutical's current Notes Receivable is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Collegium Pharmaceutical (COLL) is currently considered Possible Value Trap. The stock's GF Value™ is $46.67, compared to a current price of $27.23 — trading 41.7% below its estimated fair value. The current Notes Receivable is $0.0 Mil. Collegium Pharmaceutical's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Collegium Pharmaceutical (COLL), the current Notes Receivable is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Collegium Pharmaceutical (COLL) Overvalued in 2026?

Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued. The current stock price of $27.23 is trading 41.7% below its estimated GF Value™ of $46.67. GuruFocus considers Collegium Pharmaceutical to be Possible Value Trap.

Key valuation signals for COLL:

  • Notes Receivable: $0.0 Mil
  • GF Value™: $46.67 vs. price of $27.23 (41.7% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the COLL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Collegium Pharmaceutical Business Description

Other Exchanges 354:Germany
Address 100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
79GF Score

Get the complete analysis for COLL

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.23
Price
$46.67
GF Value